Search Within

John Frank Gerecitano

Formats
  1. Meeting Abstract (100)
  2. Journal Article (51)
  3. Book Section (1)
  4. Book Whole (1)
Groups
  1. Department of Medicine (153)
  2. Hematologic Malignancies, Division of (153)
  3. Center for Hematologic Malignancies (82)
  4. Lymphoma (75)
  5. Survivorship Research (56)
  6. Executive Committee, Center for Hematologic Malignancies (45)

More Groups

People
  1. Andrew Zelenetz (62)
  2. Paul Hamlin (60)
  3. Craig Moskowitz (57)
  4. David Straus (56)
  5. Ariela Noy (50)
  6. Matthew Matasar (48)

More People

Years
  1. 2024 (1)
  2. 2022 (3)
  3. 2021 (2)
  4. 2020 (1)
  5. 2019 (2)
  6. 2018 (8)

More Years

Publications
  1. Blood (45)
  2. Journal of Clinical Oncology (34)
  3. Haematologica (11)
  4. Clinical Cancer Research (9)
  5. Hematological Oncology (8)
  6. Annals of Oncology (7)

More Publications

Publishers
  1. American Society of Hematology (46)
  2. American Society of Clinical Oncology (34)
  3. American Association for Cancer Research (11)
  4. Ferrata Storti Foundation (11)
  5. Wiley Blackwell (10)
  6. Oxford University Press (7)

More Publishers

Results (153)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final results of phase I/II trial of vorinostat in combination with cyclophosphamide, etoposide, prednisone, and rituximab (R-CVEP) for elderly patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
    Meeting Abstract

    Straus, D. J.; Hamlin, P. A.; Matasar, M. J.; Palomba, M. L.; Drullinsky, P.; Zelenetz, A. D.; Gerecitano, J. F.; Noy, A.; Hamilton, A. M.; Wegner, B.; more...
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Risk of skin rash with the proteasome inhibitor bortezomib: Updated systematic review and meta-analysis
    Meeting Abstract

    Case, E. C.; Wu, S.; Gerecitano, J. F.; Lacouture, M. E.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • The BCL-2-specific BH3-mimetic ABT-199 (GDC-0199) is active and well-tolerated in patients with relapsed non-Hodgkin lymphoma: Interim results of a phase I study
    Meeting Abstract

    Davids, M. S.; Roberts, A. W.; Anderson, M. A.; Pagel, J. M.; Kahl, B. S.; Gerecitano, J. F.; Darden, D. E.; Nolan, C. E.; Gressick, L. A.; Yang, J. N.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • The impact of non-drug-related toxicities on the estimation of the maximum tolerated dose in phase i trials
    Journal Article

    Iasonos, A.; Gounder, M.; Spriggs, D. R.; Gerecitano, J. F.; Hyman, D. M.; Zohar, S.; O'Quigley, J.
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Augmenting advance care planning in poor prognosis cancer with a video decision aid
    Journal Article

    Volandes, A. E.; Levin, T. T.; Slovin, S.; Carvajal, R. D.; O'Reilly, E. M.; Keohan, M. L.; Theodoulou, M.; Dickler, M.; Gerecitano, J. F.; Morris, M.; more...
    Cancer (2012)

    Fulltext@MSK | Save
  • Tissue microarray analysis reveals protein expression patterns and potential biomarkers of clinical benefit to bortezomib in relapsed/refractory non-Hodgkin lymphoma
    Journal Article

    Gerecitano, J.; Gounder, S.; Teruya-Feldstein, J.; Arcila, M.; Ogilvie, S.; Gonzalez, C.; Lin, D.; Zheng, J.; Zhang, Z.; McDonald, A.; more...
    British Journal of Haematology (2012)

    Fulltext@MSK | Save
  • Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
    Journal Article

    Moskowitz, C. H.; Matasar, M. J.; Zelenetz, A. D.; Nimer, S. D.; Gerecitano, J.; Hamlin, P.; Horwitz, S.; Moskowitz, A. J.; Noy, A.; Palomba, L.; more...
    Blood (2012)

    Fulltext@MSK | Save
  • AIDS malignancy consortium (AMC) study 061: A phase I/PK study of sunitinib (S) with highly active antiretroviral therapy (HAART) in HIV+ patients with solid tumors
    Meeting Abstract

    Deeken, J. F.; Rudek, M. A.; Aboulafia, D. M.; Sullivan, R. J.; Gerecitano, J. F.; Cianfrocca, M. E.; Henry, D. H.; Ratner, L.; Dezube, B. J.; Mosby, K.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics (PK), pharmacodynamics (PD), and clinical activity of the oral AKT inhibitor GSK2141795 (GSK795) in a phase I first-in-human study
    Meeting Abstract

    Burris, H. A.; Siu, L. L.; Infante, J. R.; Wheler, J. J.; Kurkjian, C.; Opalinska, J.; Smith, D. A.; Antal, J. M.; Gauvin, J. L.; Gonzalez, T.; more...
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Risk-adapted therapy using biopsy confirmation of abnormal interim FDG-PET for patients with advanced stage diffuse large B cell lymphoma (DLBCL), and exploratory evaluation of FLT-PET
    Meeting Abstract

    Moskowitz, C. H.; Schoder, H.; Hamlin, P. A.; Gerecitano, J. F.; Horwitz, S. M.; Matasar, M. J.; Moskowitz, A. J.; Noy, A.; Palomba, M.; Portlock, C. S.; more...
    Annals of Oncology (2011)

    Fulltext@MSK | Save